...ines/ja|アンフェタミン]]などの[[stimulants/ja|覚せい剤]]であったが、2020年代初頭には[[GLP-1 receptor agonist/ja|GLP-1受容体作動薬]]が減量薬として普及した。
* ティルゼパチド、セマグルチド、リラグルチドなどの[[GLP-1 agonist/ja|GLP-1アゴニスト]]は、胃排出を遅らせ、食欲に対する神経学的な作用も有する。GLP-1アゴニストまたはGLP-1および/または[[gluca
...
22 KB (659 words) - 09:48, 8 March 2024
...的な薬物分類システムでは、これら4種類の分類が階層を形成している。例えば、[[fibrate/ja|フィブラート]]類は、同じ作用機序（[[PPAR agonist/ja|PPARアゴニスト]]）と作用機序（血中[[triglyceride/ja|トリグリセリド]]の低下）を共有し、同じ疾患（[[atheroscl
...受容体の場合、これらの活性には[[agonist/ja|作動薬]]、[[receptor antagonist/ja|拮抗薬]]、[[inverse agonist/ja|逆作動薬]]、または[[selective receptor modulator/ja|モジュレーター]]が含まれる。 酵素標的機構には、[[e
...
9 KB (422 words) - 17:29, 25 March 2024
...hipathic carboxylic acids) that share the same mechanism of action ([[PPAR agonist]]) and mode of action (reducing blood [[triglyceride]]s), and that are used
...ivities include [[agonist]], [[receptor antagonist|antagonist]], [[inverse agonist]], or [[selective receptor modulator|modulator]]. Enzyme target mechanisms
...
7 KB (907 words) - 10:49, 25 March 2024
インスリン分泌促進作用を有する持続性のある[[Glucagon-like peptide-1 receptor agonist/ja|GLP-1アナログ]]がいくつか開発されており、[[dulaglutide/ja|デュラグルチド]]（トルリシティ）、[[exenatide/j
...
4 KB (181 words) - 21:23, 11 March 2024
...GIPとは異なり、GLP-1の作用は[[2型糖尿病]]の患者でも維持されている。[[Glucagon-like peptide-1 receptor agonist/ja|グルカゴン様ペプチド-1受容体作動薬]]は、2000年代から糖尿病と肥満の治療薬として認可されるようになった。
...到達しないため、空腹時の血漿中濃度は0～15pmol/Lにしかならない。これを克服するために、GLP-1活性を高める[[GLP-1 receptor agonist/ja|GLP-1受容体作動薬]]や[[DPP-4 inhibitors/ja|DPP-4阻害薬]]が開発されてきた。[[insulin/ja|インスリ
...
17 KB (590 words) - 20:38, 11 March 2024
...hipathic carboxylic acids) that share the same mechanism of action ([[PPAR agonist]]) and mode of action (reducing blood [[triglyceride]]s), and that are used
...ivities include [[agonist]], [[receptor antagonist|antagonist]], [[inverse agonist]], or [[selective receptor modulator|modulator]]. Enzyme target mechanisms
...
7 KB (941 words) - 10:47, 25 March 2024
...timulants]] such as [[amphetamines]], in the early 2020s, [[GLP-1 receptor agonist]]s became popular for weight loss.
* [[GLP-1 agonist]]s such as tirzepatide, semaglutide, and liraglutide slow gastric emptying
...
17 KB (2,406 words) - 18:16, 7 March 2024
...timulants]] such as [[amphetamines]], in the early 2020s, [[GLP-1 receptor agonist]]s became popular for weight loss.
* [[GLP-1 agonist]]s such as tirzepatide, semaglutide, and liraglutide slow gastric emptying
...
18 KB (2,460 words) - 18:15, 7 March 2024
Several long-lasting [[Glucagon-like peptide-1 receptor agonist|GLP-1 analogs]] having insulinotropic activity have been developed, and sev
...
3 KB (442 words) - 20:49, 11 March 2024
Several long-lasting [[Glucagon-like peptide-1 receptor agonist|GLP-1 analogs]] having insulinotropic activity have been developed, and sev
...
3 KB (464 words) - 20:48, 11 March 2024
{{Pathnav|Medication|Diabetes medication|GLP-1 receptor agonist|frame=1}}
It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG
...
9 KB (1,155 words) - 10:30, 12 February 2024
{{Pathnav|Medication|Diabetes medication|GLP-1 receptor agonist|frame=1}}
It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG
...
9 KB (1,201 words) - 10:29, 12 February 2024
...d in patients with [[type 2 diabetes]]. [[Glucagon-like peptide-1 receptor agonist]]s gained approval as drugs to treat diabetes and obesity starting in the 2
...ting plasma levels of only 0–15 pmol/L. To overcome this, [[GLP-1 receptor agonist]]s and [[DPP-4 inhibitors]] have been developed to increase GLP-1 activity.
...
13 KB (1,794 words) - 09:48, 11 March 2024
...d in patients with [[type 2 diabetes]]. [[Glucagon-like peptide-1 receptor agonist]]s gained approval as drugs to treat diabetes and obesity starting in the 2
...ting plasma levels of only 0–15 pmol/L. To overcome this, [[GLP-1 receptor agonist]]s and [[DPP-4 inhibitors]] have been developed to increase GLP-1 activity.
...
14 KB (1,858 words) - 09:48, 11 March 2024
SGLT-2阻害薬、[[Glucagon-like peptide-1 receptor agonist/ja|GLP-1作動薬]]、および[[DPP-4 inhibitors/ja|DPP-4阻害薬]]を比較した[[systematic review/j
...diovascular events/ja|MACE]]のリスクを低下させるが、[[Glucagon-like peptide-1 receptor agonist/ja|GLP-1受容体作動薬]]はeGFRが高い人ほど有益であった。同様に、SGLT-2阻害薬によるリスク低減は、[[albuminuria/ja|ア
...
25 KB (941 words) - 09:18, 13 February 2024
...[[type 2 diabetes]]. Exenatide is not an analogue of GLP but rather a GLP agonist. Exenatide has only 53% homology with GLP, which increases its resistance t
[[Amylin]] agonist analogues slow gastric emptying and suppress [[glucagon]]. They have all th
...
27 KB (3,702 words) - 12:09, 4 February 2024
...[[type 2 diabetes]]. Exenatide is not an analogue of GLP but rather a GLP agonist. Exenatide has only 53% homology with GLP, which increases its resistance t
[[Amylin]] agonist analogues slow gastric emptying and suppress [[glucagon]]. They have all th
...
28 KB (3,821 words) - 16:44, 13 April 2024
** [[β-adrenergic agonist/ja|β-アドレナリン作動薬]]
...使用する。2型糖尿病は一般的に経口薬（例えば[[metformin/ja|メトホルミン]]）で治療されるが、最終的にはインスリンまたは[[GLP-1 agonist/ja|GLP-1作動薬]]による注射治療が必要となる場合もある。
...
56 KB (1,538 words) - 10:54, 16 February 2024
...art failure/ja|心不全]]、または腎疾患を有するか、またはそのリスクが高い患者では、第一選択治療として[[GLP-1 receptor agonist/ja|GLP-1受容体作動薬]]または[[SGLT2 inhibitor/ja|SGLT2阻害薬]]の使用を推奨している。これらの薬物はメトホルミンと
...
46 KB (1,357 words) - 16:36, 19 February 2024
...ant/ja|鬱血除去薬]]、吸入および全身性 [[corticosteroid/ja|コルチコステロイド]]、[[beta2-adrenergic agonist/ja|β2-アドレナリン作動薬]]、 [[anticholinergic/ja|坑コリン薬]]、[[mast cell stabilizers/ja|
...n release inhibitor/ja|ゴナドトロピン放出阻害薬]]、[[progestogen/ja|黄体ホルモン]]、[[dopamine agonist/ja|ドーパミン作動薬]]、[[estrogen/ja|エストロゲン]]、[[prostaglandin/ja|プロスタグラジン]]、[[gonado
...
58 KB (1,845 words) - 17:09, 5 November 2023